Organotins are potent activators of PPARγ and adipocyte differentiation in bone marrow multipotent mesenchymal Stromal Cells

Toxicological Sciences

Volumn 122, Issue 2, 2011, Pages 476-488

  Yanik, Susan C ^a   Baker, Amelia H ^a   Mann, Koren K ^b   Schlezinger, Jennifer J ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Adipogenesis; Bone marrow; Organotin; PPAR ; RXR

Indexed keywords

ABC TRANSPORTER A1; BEXAROTENE; DIBUTYLTIN; FATTY ACID BINDING PROTEIN 4; HETERODIMER; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; RETINOID X RECEPTOR; ROSIGLITAZONE; SHORT HAIRPIN RNA; TRIBUTYLTIN; TRIPHENYLTIN;

ADIPOCYTE; ADIPOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE MARROW CELL; C57BL 6 MOUSE; CELL DIFFERENTIATION; CELL MATURATION; CONTROLLED STUDY; DIMERIZATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG POTENCY; GENE EXPRESSION; HYPOTHESIS; LIPID STORAGE; MALE; MESENCHYMAL STEM CELL; MOUSE; MULTIPOTENT STEM CELL; NONHUMAN; PROTEIN EXPRESSION; STROMA CELL;

ADIPOCYTES; ADIPOGENESIS; ANIMALS; BONE MARROW; BONE MARROW CELLS; CELL DIFFERENTIATION; CELLS, CULTURED; FATTY ACID-BINDING PROTEINS; MALE; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED C57BL; ORGANOTIN COMPOUNDS; PPAR GAMMA; RETINOID X RECEPTORS; THIAZOLIDINEDIONES; TRIALKYLTIN COMPOUNDS;

EID: 80051678891     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfr140     Document Type: Article

References (49)

1. Akune, T., Ohba, S., Kamekura, S., Yamaguchi, M., Chung, U. I., Kubota, N., Terauchi, Y., Harada, Y., Azuma, Y., Nakamura, K., et al. (2004). PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J. Clin. Invest. 113, 846-855.
2. Ali, A. A., Weinstein, R. S., Stewart, S. A., Parfitt, A. M., Manolagas, S. C., and Jilka, R. L. (2005). Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 146, 1226-1235.
3. Antizar-Ladislao, B. (2008). Environmental levels, toxicity and human exposure to tributyltin (TBT)-contaminated marine environment. a review. Environ. Int. 34, 292-308.
4. Carfi, M., Croera, C., Ferrario, D., Campi, V., Bowe, G., Pieters, R., and Gribaldo, L. (2008). TBTC induces adipocyte differentiation in human bone marrow long term culture. Toxicology 249, 11-18.
5. Cha, B. S., Ciaraldi, T. P., Carter, L., Nikoulina, S. E., Mudaliar, S., Mukherjee, R., Paterniti, J. R., Jr., and Henry, R. R. (2001). Peroxisome proliferator-activated receptor (PPAR) gamma and retinoid X receptor (RXR) agonists have complementary effects on glucose and lipid metabolism in human skeletal muscle. Diabetologia 44, 444-452.
6. Chan, G. K., and Duque, G. (2002). Age-related bone loss: old bone, new facts. Gerontology 48, 62-71.
7. Cock, T. A., Back, J., Elefteriou, F., Karsenty, G., Kastner, P., Chan, S., and Auwerx, J. (2004). Enhanced bone formation in lipodystrophic PPARgamma(hyp/hyp) mice relocates haematopoiesis to the spleen. EMBO. Rep. 5, 1007-1012.
8. Cornelissen, G., Pettersen, A., Nesse, E., Eek, E., Helland, A., and Breedveld, G. D. (2008). The contribution of urban runoff to organic contaminant levels in harbour sediments near two Norwegian cities. Mar. Pollut. Bull. 56, 565-573.
9. Cui, H., Okuhira, K., Ohoka, N., Naito, M., Kagechika, H., Hirose, A., and Nishimaki-Mogami, T. (2010). Tributyltin chloride induces ABCA1 expression and apolipoprotein A-I-mediated cellular cholesterol efflux by activating LXRalpha/RXR. Biochem. Pharmacol. 81, 819-824.
10. Ducharme, N. A., and Bickel, P. E. (2008). Lipid droplets in lipogenesis and lipolysis. Endocrinology 149, 942-949.
11. Feige, J. N., Gelman, L., Rossi, D., Zoete, V., Metivier, R., Tudor, C., Anghel, S. I., Grosdidier, A., Lathion, C., Engelborghs, Y., et al. (2007). The endocrine disruptor monoethyl-hexyl-phthalate is a selective peroxisome proliferator-activated receptor gamma modulator that promotes adipogenesis. J. Biol. Chem. 282, 19152-19166.
12. Fromme, H., Mattulat, A., Lahrz, T., and Ruden, H. (2005). Occurrence of organotin compounds in house dust in Berlin (Germany). Chemosphere 58, 1377-1383.
13. Gampe, R. T., Jr., Montana, V. G., Lambert,M. H.,Miller, A. B., Bledsoe, R. K., Milburn, M. V., Kliewer, S. A., Willson, T. M., and Xu, H. E. (2000). Asymmetry in the PPARgamma/RXRalpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors. Mol. Cell. 5, 545-555.
14. Gimble, J. M., Robinson, C. E., Wu, X., Kelly, K. A., Rodriguez, B. R., Kliewer, S. A., Lehmann, J. M., and Morris, D. C. (1996). Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells. Mol. Pharmacol. 50, 1087-1094.
15. Grun, F., Watanabe, H., Zamanian, Z., Maeda, L., Arima, K., Cubacha, R., Gardiner, D. M., Kanno, J., Iguchi, T., and Blumberg, B. (2006). Endocrinedisrupting organotin compounds are potent inducers of adipogenesis in vertebrates. Mol. Endocrinol. 20, 2141-2155.
16. Gurnell, M., Wentworth, J. M., Agostini, M., Adams, M., Collingwood, T. N., Provenzano, C., Browne, P. O., Rajanayagam, O., Burris, T. P., Schwabe, J.W., et al. (2000). A dominant-negative peroxisome proliferator-activated receptor gamma (PPARgamma) mutant is a constitutive repressor and inhibits PPARgamma-mediated adipogenesis. J. Biol. Chem. 275, 5754-5759.
17. Hiromori, Y., Nishikawa, J., Yoshida, I., Nagase, H., and Nakanishi, T. (2009). Structure-dependent activation of peroxisome proliferator-activated receptor (PPAR) gamma by organotin compounds. Chem. Biol. Interact. 180, 238-244.
18. Idres, N., Marill, J., and Chabot, G. G. (2005). Regulation of CYP26A1 expression by selective RAR and RXR agonists in human NB4 promyelocytic leukemia cells. Biochem. Pharmacol. 69, 1595-1601.
19. Kaddatz, K., Adhikary, T., Finkernagel, F., Meissner, W., Muller-Brusselbach, S., and Muller, R. (2010). Transcriptional profiling identifies functional interactions of TGF beta and PPAR beta/delta signaling: synergistic induction of ANGPTL4 transcription. J. Biol. Chem. 285, 29469-29479.
20. Kanayama, T., Kobayashi, N., Mamiya, S., Nakanishi, T., and Nishikawa, J. (2005). Organotin compounds promote adipocyte differentiation as agonists of the peroxisome proliferator-activated receptor gamma/retinoid X receptor pathway. Mol. Pharmacol. 67, 766-774.
21. Kannan, K., Takahashi, S., Fujiwara, N., Mizukawa, H., and Tanabe, S. (2010). Organotin compounds, including butyltins and octyltins, in house dust from Albany, New York, USA. Arch. Environ. Contam. Toxicol. 58, 901-907.
22. Kim, J. B., Wright, H. M., Wright, M., and Spiegelman, B. M. (1998). ADD1/SREBP1 activates PPARgamma through the production of endogenous ligand. Proc. Natl. Acad. Sci. U.S.A. 95, 4333-4337.
23. Kirchner, S., Kieu, T., Chow, C., Casey, S., and Blumberg, B. (2010). Prenatal exposure to the environmental obesogen tributyltin predisposes multipotent stem cells to become adipocytes. Mol. Endocrinol. 24, 526-539.
24. Lala, D. S., Mukherjee, R., Schulman, I. G., Koch, S. S., Dardashti, L. J., Nadzan, A. M., Croston, G. E., Evans, R. M., and Heyman, R. A. (1996). Activation of specific RXR heterodimers by an antagonist of RXR homodimers. Nature 383, 450-453.
25. Lazarenko, O. P., Rzonca, S. O., Hogue, W. R., Swain, F. L., Suva, L. J., and Lecka-Czernik, B. (2007). Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology 148, 2669-2680.
26. le Maire, A., Grimaldi, M., Roecklin, D., Dagnino, S., Vivat-Hannah, V., Balaguer, P., and Bourguet, W. (2009). Activation of RXR-PPAR heterodimers by organotin environmental endocrine disruptors. EMBO Rep. 10, 367-373.
27. Lecka-Czernik, B., Ackert-Bicknell, C., Adamo, M. L., Marmolejos, V., Churchill, G. A., Shockley, K. R., Reid, I. R., Grey, A., and Rosen, C. J. (2007). Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo. Endocrinology 148, 903-911.
28. Lee, G., Elwood, F., McNally, J., Weiszmann, J., Lindstrom, M., Amaral, K., Nakamura, M., Miao, S., Cao, P., Learned, R. M., et al. (2002). T0070907, a selective ligand for peroxisome proliferatoractivated receptor gamma, functions as an antagonist of biochemical and cellular activities. J. Biol. Chem. 277, 19649-19657.
29. Lee, N. K., Sowa, H., Hinoi, E., Ferron, M., Ahn, J. D., Confavreux, C., Dacquin, R., Mee, P. J., McKee, M. D., Jung, D. Y., et al. (2007). Endocrine regulation of energy metabolism by the skeleton. Cell 130, 456-469.
30. Lefebvre, P., Benomar, Y., and Staels, B. (2010). Retinoid X receptors: common heterodimerization partners with distinct functions. Trends. Endocrinol. Metab. 21, 676-683.
31. Lefterova, M. I., and Lazar, M. A. (2009). New developments in adipogenesis. Trends. Endocrinol. Metab. 20, 107-114.
32. Loke, Y. K., Singh, S., and Furberg, C. D. (2009). Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. Can. Med. Assoc. J. 180, 32-39.
33. McDonough, A. K., Rosenthal, R. S., Cao, X., and Saag, K. G. (2008). The effect of thiazolidinediones on BMD and osteoporosis. Nat. Clin. Pract. Endocrinol. Metab. 4, 507-513.
34. Moerman, E. J., Teng, K., Lipschitz, D. A., and Lecka-Czernik, B. (2004). Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: the role of PPAR-gamma2 transcription factor and TGF-beta/BMP signaling pathways. Aging Cell. 3, 379-389.
35. Nakanishi, T., Nishikawa, J., Hiromori, Y., Yokoyama, H., Koyanagi, M., Takasuga, S., Ishizaki, J., Watanabe, M., Isa, S., Utoguchi, N., et al. (2005). Trialkyltin compounds bind retinoid X receptor to alter human placental endocrine functions. Mol. Endocrinol. 19, 2502-2516.
36. Naveiras, O., Nardi, V., Wenzel, P. L., Hauschka, P. V., Fahey, F., and Daley, G. Q. (2009). Bone-marrow adipocytes as negative regulators of the haematopoietic microenvironment. Nature 460, 259-263.
37. Nishikawa, K., Nakashima, T., Takeda, S., Isogai, M., Hamada, M., Kimura, A., Kodama, T., Yamaguchi, A., Owen, M. J., Takahashi, S., et al. (2010). Maf promotes osteoblast differentiation in mice by mediating the age-related switch in mesenchymal cell differentiation. J. Clin. Invest. 120, 3455-3465.
38. Pietrangeli, C., Hayashi, S.-I., and Kincade, P. (1988). Stromal cell lines which support lymphocyte growth: characterization, sensitivity to radiation and responsiveness to growth factors. Eur. J. Immunol. 18, 863-872.
39. Rosen, C. J., and Bouxsein, M. L. (2006). Mechanisms of disease: is osteoporosis the obesity of bone? Nat. Clin. Pract. Rheumatol. 2, 35-43.
40. Rzonca, S. O., Suva, L. J., Gaddy, D., Montague, D. C., and Lecka-Czernik, B. (2004). Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 145, 401-406.
41. Sato, M., Yajima, Y., Kawashima, S., Tanaka, K., and Kagechika, H. (2001). Synergistic potentiation of thiazolidinedione-induced ST 13 preadipocyte differentiation by RAR synergists. Biochem. Biophys. Res. Commun. 280, 646-651.
42. Schulman, I. G., Shao, G., and Heyman, R. A. (1998). Transactivation by retinoid X receptor-peroxisome proliferators-activated receptor (PPARc) heterodimers: intermolecular synergy requires only the PPARc hormonedependent activation function. Mol. Cell Biol. 18, 3483-3494.
43. Syversen, U., Stunes, A. K., Gustafsson, B. I., Obrant, K. J., Nordsletten, L., Berge, R., Thommesen, L., and Reseland, J. E. (2009). Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)alpha agonist fenofibrate and the PPARgamma agonist pioglitazone. BMC Endocr. Disord. 9, 10.
44. Szeles, L., Poliska, S., Nagy, G., Szatmari, I., Szanto, A., Pap, A., Lindstedt, M., Santegoets, S. J., Ruhl, R., Dezso, B., et al. (2010). Research resource: transcriptome profiling of genes regulated by RXR and its permissive and nonpermissive partners in differentiating monocyte-derived dendritic cells. Mol. Endocrinol. 24, 2218-2231.
45. Tontonoz, P., Hu, E., Graves, R. A., Budavari, A. I., and Spiegelman, B. M. (1994). mPPARc2: tissue-specific regulator of an adipocyte enhancer. Genes. Dev. 8, 1224-1234.
46. Tontonoz, P., Singer, S., Forman, B. M., Sarraf, P., Fletcher, J. S., Fletcher, C. D., Brun, R. P., Mueller, E., Altiok, S., Oppenheim, H., et al. (1997). Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferators-activated receptor γ and the retinoid X receptor. Proc. Nat. Acad. Sci. U.S.A. 94, 237-241.
47. Venkateswaran, A., Laffitte, B. A., Joseph, S. B., Mak, P. A., Wilpitz, D. C., Edwards, P. A., and Tontonoz, P. (2000). Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha. Proc. Natl. Acad. Sci. U.S.A. 97, 12097-12102.
48. Wu, J. Y., Purton, L. E., Rodda, S. J., Chen, M., Weinstein, L. S., McMahon, A. P., Scadden, D. T., and Kronenberg, H. M. (2008). Osteoblastic regulation of B lymphopoiesis is mediated by Gs{alpha}-dependent signaling pathways. Proc. Natl. Acad. Sci. U.S.A. 105, 16976-16981.
49. Xu, M., and Miller, M. S. (2004). Determination of murine fetal Cyp1a1 and 1b1 expression by real-time fluorescence reverse transcription-polymerase chain reaction. Toxicol. Appl. Pharmacol. 201, 295-302.